Related Experiment Videos
Neurologic complications in oral polio vaccine recipients
Insights
Vaccine-related poliovirus infection caused severe neurologic issues in four infants. The observed incidence in oral poliovirus vaccine recipients was significantly higher than predicted.
Area of Science:
- Pediatric Neurology
- Infectious Diseases
- Vaccinology
Background:
- Investigating neurologic abnormalities in infants receiving oral poliovirus vaccine (OPV).
- Assessing potential links between vaccination and neurological conditions in young children.
- Understanding vaccine-related complications of poliovirus immunization.
Observation:
- Four infants (3-24 months) presented with neurologic symptoms consistent with vaccine-related poliovirus infection.
- Patients received oral poliovirus vaccine and DTaP injection prior to symptom onset.
- A vaccine-like poliovirus strain was isolated from each child, with persistent symptoms including paralysis and cerebral atrophy.
Findings:
- The incidence of vaccine-related poliovirus infection was 0.058 per 100,000 OPV recipients annually in Indiana.
- This observed incidence was significantly greater than predicted, indicating an underrecognized risk.
- Immune function varied, with normal responses in some and immunodeficiency in others, suggesting complex interactions.
Implications:
- Highlights the potential for vaccine-derived poliovirus to cause severe neurologic disease in infants.
- Suggests a need for enhanced surveillance of vaccine-related infections.
- Informs vaccination strategies and risk-benefit analyses for oral poliovirus vaccine.
Abstract:
Between April 1982 and June 1983 four children 3 to 24 months of age were referred for evaluation of neurologic abnormalities found to be compatible with vaccine-related poliovirus infection, which had not been suspected by referring physicians. Patients were epidemiologically unrelated residents of Indiana, and none had prior symptoms suggestive of immunodeficiency. All had received poliovirus vaccine orally (first dose in three, fourth dose in one) and a diphtheria-tetanus-pertussis injection in the left anterior thigh within 30 days of symptoms. A vaccine-like strain of poliovirus was isolated from each patient, and each had symptoms (left leg paralysis in three; developmental regression, spasticity, and progressive fatal cerebral atrophy in one) persisting for at least 6 months. Immune function was normal in two with poliovirus type 3 infection, and abnormal (hypogammaglobulinemia, combined immunodeficiency) in two with type 1 and type 2 infection, respectively. The incidence of observed vaccine-related poliovirus infection in Indiana recipients of orally administered poliovirus vaccine was 0.058 per 100,000 per year, significantly greater (P less than 0.001) than predicted.